

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-101078-PIP01-23-M03

Scope of the Application

Active Substance(s)

OLAPARIB

Condition(s)

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic, and lymphoid tissue).

Pharmaceutical Form(s)

Tablet Age-appropriate oral solid dosage form

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

AstraZeneca UK Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, AstraZeneca UK Limited submitted to the licensing authority on 24/04/2026 16:29 BST an application for a Modification

The procedure started on 18/05/2026 12:33 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101078-PIP01-23-M03

Of 13/07/2026 10:55 BST

On the adopted decision for OLAPARIB (MHRA-101078-PIP01-23-M03) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for OLAPARIB, Film-coated tablet Age-appropriate oral solid dosage form , ORAL USE .

This decision is addressed to AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge, UNITED KINGDOM, CB2 0AA

ANNEX I

1. Waiver

1.1 Condition:

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic, and lymphoid tissue). The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 6 years of age. Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral solid dosage form Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic, and lymphoid tissue).

2.2 Indication(s) targeted by the PIP:

Treatment of paediatric patients from 6 years to less than 18 years old with homologous recombination repair (HRR) mutated solid tumours.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 6 years to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Film-coated tablet Age-appropriate oral solid dosage form

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an age-appropriate oral solid dosage form.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	3	Study 2 (D0816C00025) Open-label, multicentre study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of olaparib monotherapy in paediatric patients with relapsed or refractory solid tumours (non-CNS and primary CNS tumours) with a homologous recombination repair (HRR) deficiency for whom there are no standard treatment options. Study 3 This study was deleted during procedure MHRA-101078-PIP01-23-M03. Study 4 This study was deleted during procedure MHRA-101078-PIP01-23-M03.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	30/04/2025
Deferral of one or more studies contained in the paediatric investigation plan:	Yes